Naloxegol

Pre-clinicalCompleted

1 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Opioid-induced Constipation

Conditions

Opioid-induced Constipation

Trial Timeline

Sep 21, 2017 → Oct 31, 2019

NCT ID

NCT04173858

About Naloxegol

Naloxegol is a pre-clinical stage product being developed by Kyowa Kirin for Opioid-induced Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT04173858. Target conditions include Opioid-induced Constipation.

What happened to similar drugs?

4 of 20 similar drugs in Opioid-induced Constipation were approved

Approved (4) Terminated (8) Active (9)

✅Naldemedine + PlaceboShionogiApproved

✅methylnaltrexone + placeboBausch HealthApproved

✅Methylnaltrexone bromideBausch HealthApproved

✅Methylnaltrexone + PlaceboBausch HealthApproved

🔄Naldemedine + PlaceboShionogiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03638440	Pre-clinical	Completed	Aug 16, 2018	Mar 5, 2020	Opioid Induced Constipation
NCT04173858	Pre-clinical	Completed	Sep 21, 2017	Oct 31, 2019	Opioid-induced Constipation
NCT02813148	Pre-clinical	Completed	Aug 1, 2015	Jan 1, 2020	Opioid Induced Constipation
NCT02099591	Phase 1	Completed	Nov 1, 2014	Apr 1, 2021	Constipation, Signs and Symptoms, Digestive

Competing Products

20 competing products in Opioid-induced Constipation

See all competitors

Product	Company	Stage	Hype Score
Naldemedine + Placebo	Shionogi	Phase 3	40
Naldemedine + Placebo	Shionogi	Approved	50
Naldemedine	Shionogi	Phase 1/2	39
Naldemedine + Placebo	Shionogi	Phase 3	40
Placebo + Naldemedine	Shionogi	Phase 2	35
Naldemedine + Placebo	Shionogi	Phase 3	40
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	32
NKTR-118 + Usual care	AstraZeneca	Phase 3	40
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
Naloxegol + Placebo Oral Capsule	AstraZeneca	Phase 2	27
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
Tegaserod	Novartis	Phase 3	32
Tegaserod	Novartis	Phase 3	32
Methylnaltrexone bromide + Placebo	Pfizer	Phase 2	35
ALKS 37 + Placebo	Alkermes	Phase 2	32